



ELISA Kit

Catalog # **KHR9061 (96 tests)**

Human
EGFR
(Full length)

www.invitrogen.com

Invitrogen Corporation

542 Flynn Road, Camarillo, CA 93012

Tel: 800-955-6288

E-mail: techsupport@invitrogen.com

Table of Contents

Table of Contents.....	3
Contents and Storage.....	4
Introduction.....	5
Purpose.....	5
Principle of the Method.....	5
Background Information.....	6
Methods.....	7
Materials Needed But Not Provided.....	7
Procedural Notes.....	7
Procedure For Protein Extraction From Cells Or Tissues.....	8
Preparation of Reagents.....	9
Assay Procedure.....	10
Typical Data.....	11
Performance Characteristics.....	12
Sensitivity.....	12
Precision.....	12
Recovery.....	13
Specificity.....	13
Linearity of Dilution.....	14
Parallelism.....	14
Limitations of the Procedure.....	14
Appendix.....	15
Troubleshooting Guide.....	15
Technical Support.....	16
References.....	17

Contents and Storage

Storage

Store at 2 to 8°C.

Contents

Reagents Provided	96 Test Kit
<i>Hu EGFR Standard</i> , lyophilized. Contains 0.1% sodium azide. Refer to vial label for quantity and reconstitution volume.	2 vials
<i>Standard Diluent Buffer*</i> . Contains 0.1% sodium azide; 25 mL per bottle.	1 bottle
<i>Antibody Coated Wells</i> . 12 x 8 Well Strips.	1 plate
<i>Hu EGFR Detection Antibody</i> . Contains 0.1% sodium azide; 11 mL per bottle.	1 bottle
<i>Anti-Rabbit IgG HRP (100X)</i> . Contains 3.3 mM thymol; 0.125 mL per vial.	1 vial
<i>HRP Diluent</i> . Contains 3.3 mM thymol; 25 mL per bottle.	1 bottle
<i>Wash Buffer Concentrate (25X)</i> . 100 mL per bottle.	1 bottle
<i>Stabilized Chromogen, Tetramethylbenzidine (TMB)</i> . 25 mL per bottle.	1 bottle
<i>Stop Solution</i> ; 25 mL per bottle.	1 bottle
<i>Plate Covers</i> , adhesive strips.	3
* If precipitates are found in standard diluent buffer, they should be completely dissolved by warming to room temperature before use.	

Disposal Note

This kit contains materials with small quantities of sodium azide. Sodium azide reacts with lead and copper plumbing to form explosive metal azides. Upon disposal, flush drains with a large volume of water to prevent azide accumulation. Avoid ingestion and contact with eyes, skin and mucous membranes. In case of contact, rinse affected area with plenty of water. Observe all federal, state and local regulations for disposal.

Safety

All blood components and biological materials should be handled as potentially hazardous. Follow universal precautions as established by the Centers for Disease Control and Prevention and by the Occupational Safety and Health Administration when handling and disposing of infectious agents.

Introduction

Purpose

The Invitrogen Human full length EGFR ELISA is designed to detect and quantify the levels of full length EGFR protein, independent of its phosphorylation state. It does not detect 110 kDa truncated EGFR, which does not contain cytoplasmic tyrosine kinase domain. This assay is intended to detect full length EGFR from lysates of cells and tissues and can be used to normalize the EGFR content of the samples when examining quantities of phosphorylated sites on EGFR using other Invitrogen kits (Cat. No. KHR9071 or KHR9081).

For Research Use Only. CAUTION: Not for human or animal therapeutic or diagnostic use.

Principle of the Method

The Invitrogen Human full length EGFR kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A monoclonal antibody specific for human EGFR (regardless of phosphorylation state) has been coated onto the wells of the microtiter strips provided. Samples, including a standard containing human EGFR, control specimens, and unknowns, are pipetted into these wells. During the first incubation, the human EGFR antigen binds to the immobilized (capture) antibody. After washing, an antibody specific for human C-terminus of EGFR is added to the wells. During the second incubation, this antibody serves as a detection antibody by binding to the immobilized EGFR protein captured during the first incubation. After removal of excess detection antibody, a horseradish peroxidase-labeled Anti-Rabbit IgG (Anti-Rabbit IgG HRP) is added. This binds to the detection antibody to complete the four-member sandwich. After a third incubation and washing to remove all the excess Anti-Rabbit IgG HRP, a substrate solution is added, which is acted upon by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of human full length EGFR present in the original specimen.

Background Information

The epidermal growth factor receptor (EGFR) belongs to the family of receptor tyrosine kinases (RTKs), which regulate cell growth, survival, proliferation and differentiation. EGFR, also known as ErbB1, is most related to the other members of the EGFR family of RTKs including HER2/ErbB2/neu, HER3/ErbB3 and HER4/ErbB4. EGFR at full length is a 170 kDa type I transmembrane glycoprotein which consists of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and an intracellular segment harboring the highly conserved, tyrosine kinase domain. Several deletions in the extra- and intracellular domain of the EGFR have been found in a number of tumors. For example, EGFRvIII is a 145 kDa protein with a deletion of exons 2-7 in EGFR mRNA. A 110 kDa truncated EGFR without cytoplasmic domain is observed in the culture supernatant from A431 cells, a human epidermoid carcinoma cell line.

EGFR is activated by the binding of ligands such as EGF, transforming growth factor α (TGF α), amphiregulin, β -cellulin, heparin binding EGF-like growth factor (HB-EGF) and epiregulin. The binding causes EGFR homo- and heterodimerization and rapid activation of its intrinsic tyrosine kinase followed by autophosphorylation of multiple tyrosine residues in the cytoplasmic domain. The phosphorylation of tyrosine residues in the C-terminal tail of the molecule serves as binding sites for cytosolic signaling proteins containing Src homology 2 (SH2) domains. Several sites of *in vivo* phosphorylation have been identified in the EGFR including pY⁸⁴⁵, pY⁹⁹², pY¹⁰⁶⁸, pY¹⁰⁸⁶, and pY¹¹⁷³. These sites bind and activate a variety of downstream signaling proteins which contain SH2 domains,

including growth factor receptor-binding protein 2 (Grb2), Src homology and collagen domain protein (Shc) and phospholipase C-g (PLC- γ). Binding of these or other signaling proteins to the receptor and/or their phosphorylation results in transmission of subsequent signaling events that culminate in DNA synthesis and cell division.

Methods

Materials Needed But Not Provided

- Microtiter plate reader (at or near 450 nm) with software
 - Calibrated adjustable precision pipettes
 - Distilled or deionized water
 - Plate washer: automated or manual (squirt bottle, manifold dispenser, etc.)
 - Glass or plastic tubes for diluting solutions
 - Absorbent paper towels
 - Calibrated beakers and graduated cylinders
-

Procedural Notes

1. When not in use, kit components should be refrigerated. All reagents should be warmed to room temperature before use.
 2. **Microtiter plates should be allowed to come to room temperature before opening the foil bags.** Once the desired number of strips has been removed, immediately reseal the bag and store at 2 to 8°C to maintain plate integrity.
 3. Samples should be collected in pyrogen/endotoxin-free tubes.
 4. Samples should be frozen if not analyzed shortly after collection. Avoid multiple freeze-thaw cycles of frozen samples. Thaw completely and mix well prior to analysis.
 5. When possible, avoid use of badly hemolyzed or lipemic sera. If large amounts of particulate matter are present, centrifuge or filter prior to analysis.
 6. It is recommended that all standards, controls and samples be run in duplicate.
 7. When pipetting reagents, maintain a consistent order of addition from well-to-well. This ensures equal incubation times for all wells.
 8. **Do not mix or interchange different reagent lots from various kit lots.**
 9. Do not use reagents after the kit expiration date.
 10. Absorbances should be read immediately, but can be read up to 2 hours after assay completion. For best results, keep plate covered in the dark.
 11. In-house controls should be run with every assay. If control values fall outside pre-established ranges, the accuracy of the assay is suspect.
 12. All residual wash liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. **Never** insert absorbent paper directly into the wells.
 13. Because Stabilized *Chromogen* is light sensitive, avoid prolonged exposure to light. Avoid contact between chromogen and metal, or color may develop.
-

Directions for Washing

- **Incomplete washing will adversely affect the test outcome.** All washing must be performed with the *Wash Buffer Concentrate (25X)* provided.
 - Washing can be performed manually as follows: completely aspirate the liquid from all wells by gently lowering an aspiration tip into the bottom of each well. Take care not to scratch the inside of the well. After aspiration, fill the wells with at least 0.4 ml of diluted *Wash Buffer*. Let soak for 15 to 30 seconds, and then aspirate the liquid. Repeat as directed under Assay Procedure. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.
 - Alternatively, the diluted *Wash Buffer* may be put into a squirt bottle. If a squirt bottle is used, flood the plate with the diluted *Wash Buffer*, completely filling all wells. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.
 - If using an automated washer, follow the washing instructions carefully.
-

Procedure For Protein Extraction From Cells Or Tissues

Recommended Formulation of Cell or Tissue Extraction Buffer:

- 10 mM Tris, pH 7.4
- 100 mM NaCl
- 1 mM EDTA
- 1 mM EGTA
- 1 mM NaF
- 20 mM $\text{Na}_4\text{P}_2\text{O}_7$
- 2 mM Na_3VO_4
- 1% Triton X-100
- 10% glycerol
- 0.1% SDS
- 0.5% deoxycholate

This Cell Extraction Buffer (Invitrogen, Cat. # FNN0011) needs the following reagents to be added:

- 1 mM PMSF (stock is 0.3 M in DMSO)
- Protease inhibitor cocktail (e.g., Sigma Cat. # P-2714) (reconstituted according to manufacturer's guideline). Add 500 μl per 5 ml Cell Extraction Buffer.

The Cell Extraction Buffer is stable for 2 to 3 weeks at 4°C or for up to 6 months when aliquoted (without protease inhibitors and PMSF added) and stored at -20°C. When stored frozen, the buffer should be thawed on ice. **Important:** add the protease inhibitors just before using. The stability of protease inhibitor supplemented Cell Extraction Buffer is 24 hours at 4°C. PMSF is very unstable and must be added prior to use, even if added previously.

The following protocol has been applied to several cell lines using this Cell Extraction Buffer. Researchers may optimize the cell extraction procedures that work best in their hands.

1. Collect cells in PBS by centrifugation (non-adherent) or scraping from culture flasks (adherent).
 2. Wash cells twice with cold PBS.
 3. Remove and discard the supernatant and collect the cell pellet. (At this point the cell pellet can be frozen at -80°C and lysed at a later date).
 4. Lyse the cell pellet in Cell Extraction Buffer for 30 minutes on ice with vortexing at 10 minute intervals. The volume of Cell Extraction Buffer depends on the cell number in cell pellet and expression of EGFR. For example, 10^8 A431 cells grown in RPMI plus 10% FBS can be extracted in 1 ml of Cell Extraction Buffer. Under these conditions, use of 0.1-1 μl of the clarified cell lysate diluted to a volume of 100 μl /well in Standard Diluent Buffer (See **Assay Procedure**) is sufficient for the detection of EGFR.
 5. Transfer lysates to microcentrifuge tubes and centrifuge at 13,000 rpm for 10 minutes at 4°C.
 6. Aliquot the clear lysate to clean microcentrifuge tubes. These samples are ready for assay. Lysates can be stored at -80°C. Avoid multiple freeze-thaw cycles.
-

Preparation of Reagents


Dilution of Standard

Note: The Human EGFR (p170) Standard is prepared from human A431 cells and is calibrated against the mass of affinity purified EGFR.

1. Reconstitute *EGFR Standard* with *Standard Diluent Buffer*. Refer to standard vial label for instructions. Swirl or mix gently and allow to sit for 10 minutes to ensure complete reconstitution. Label as 20 ng/ml EGFR. Use the standard within 1 hour of reconstitution.
2. Add 0.25 ml of *Standard Diluent Buffer* to each of 6 tubes labeled 10, 5, 2.5, 1.25, 0.625, and 0.312 ng/ml human EGFR.
3. Make serial dilutions of the standard as described in the following dilution diagram. Mix thoroughly between steps.

Note

Remaining reconstituted standard should be discarded or frozen in aliquots at -80 °C for further use. Standard can be frozen and thawed one time only without loss of activity.



Preparing IgG-HRP

Note: Prepare within 15 minutes of usage. The *Anti-Rabbit IgG HRP (100X)* is in 50% glycerol, which is viscous. To ensure accurate dilution, allow the *Anti-Rabbit IgG HRP (100X)* to reach room temperature. Gently mix. Pipette the *Anti-Rabbit IgG HRP (100X)* slowly. Remove excess concentrate solution from pipette tip by gently wiping with clean absorbent paper.

1. Dilute 10 µl of this 100X concentrated solution with 1 ml of *HRP Diluent* for each 8-well strip used in the assay. Label as Anti-rabbit IgG-HRP Working Solution.
2. Return the unused *Anti-Rabbit IgG HRP (100X)* to the refrigerator.

# of 8-Well Strips	Volume of Anti-Rabbit IgG HRP (100X)	Volume of Diluent
2	20 µl solution	2 ml
4	40 µl solution	4 ml
6	60 µl solution	6 ml
8	80 µl solution	8 ml
10	100 µl solution	10 ml
12	120 µl solution	12 ml

Dilution of Wash Buffer

1. Allow the *Wash Buffer Concentrate (25X)* to reach room temperature and mix to ensure that any precipitated salts have redissolved. Dilute 1 volume of the *Wash Buffer Concentrate (25X)* with 24 volumes of deionized water (e.g., 50 ml may be diluted up to 1.25 liters, 100 ml may be diluted up to 2.5 liters). Label as Working Wash Buffer.
 2. Store both the concentrate and the Working Wash Buffer in the refrigerator. The diluted buffer should be used within 14 days.
-

Assay Procedure

Be sure to read the *Procedural Notes* section before carrying out the assay.

Allow all reagents to reach room temperature before use. Gently mix all liquid reagents prior to use.

Note: A standard curve must be run with each assay.

1. Determine the number of 8-well strips needed for the assay. Insert these in the frame(s) for current use. (Re-bag extra strips and frame. Store these in the refrigerator for future use.)
2. Add 100 μ l of the *Standard Diluent Buffer* to the zero standard wells. Well(s) reserved for chromogen blank should be left empty.
3. Add 100 μ l of standards and diluted samples or controls to the appropriate microtiter wells. Samples prepared in Cell Extraction Buffer must be diluted 1:10 or greater in *Standard Diluent Buffer* (for example, 10 μ l sample into 90 μ l buffer). While a 1:10 sample dilution has been found to be satisfactory, higher dilutions such as 1:50 or 1:100 may be optimal. The dilution chosen should be optimized for each experimental system. Tap gently on side of plate to mix.
4. Cover wells with *plate cover* and incubate for **2 hours at room temperature**.
5. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See **Directions for Washing**.
6. Pipette 100 μ L of *Hu EGFR Detection Antibody* solution into each well except the chromogen blank(s). Tap gently on the side of the plate to mix.
7. Cover wells with *plate cover* and incubate for **1 hour at room temperature**.
8. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See **Directions for Washing**.
9. Add 100 μ l Anti-Rabbit IgG HRP Working Solution to each well except the chromogen blank(s). (Prepare the working dilution as described in **Preparing IgG HRP**).
10. Cover wells with the *plate cover* and incubate for **30 minutes at room temperature**.
11. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See **Directions for Washing**.
12. Add 100 μ l of *Stabilized Chromogen* to each well. The liquid in the wells will begin to turn blue.
13. Incubate for **30 minutes at room temperature and in the dark**. **Note: Do not cover the plate with aluminum foil or metalized mylar.** The incubation time for chromogen substrate is often determined by the microtiter plate reader used. Many plate readers have the capacity to record a maximum optical density (O.D.) of 2.0. The O.D. values should be monitored and the substrate reaction stopped before the O.D. of the positive wells exceeds the limits of the instrument. The O.D. values at 450 nm can only be read after the *Stop Solution* has been added to each well. If using a reader that records only to 2.0 O.D., stopping the assay after 20 to 25 minutes is suggested.
14. Add 100 μ l of *Stop Solution* to each well. Tap side of plate gently to mix. The solution in the wells should change from blue to yellow.

15. Read the absorbance of each well at 450 nm having blanked the plate reader against a chromogen blank composed of 100 μ l each of *Stabilized Chromogen* and *Stop Solution*. Read the plate within 2 hours after adding the *Stop Solution*.
16. Use a curve fitting software to generate the standard curve. A four parameter algorithm provides the best standard curve fit.
17. Read the concentrations for unknown samples and controls from the standard curve. **Multiply value(s) obtained for sample(s) by the appropriate dilution factor to correct for the dilution in step 3.** Samples producing signals greater than that of the highest standard should be diluted in *Standard Diluent Buffer* and reanalyzed.

Typical Data (Example)

The following data were obtained for the various standards over the range of 0 to 20 ng/ml human EGFR.

Standard EGFR (ng/ml)	Optical Density (450 nm)
20	2.882
10	1.778
5	0.998
2.5	0.610
1.25	0.330
0.63	0.229
0.32	0.154
0	0.103

Lysates from various cell lines were adjusted to a concentration of 100 mg/ml protein. The full length EGFR content of each was determined by ELISA, and reported below:

A431: 14.40 ng/ml
 HeLa: 2.256 ng/ml
 Jurket: 0.35 ng/ml
 MCF-7: 0.47 ng/ml


Performance Characteristics

Sensitivity

The analytical sensitivity of this assay is < 0.300 ng/ml of human full length EGFR. This was determined by adding two standard deviations to the mean O.D. obtained when the zero standard was assayed 30 times.

The sensitivity of this ELISA was compared to Western blotting using known quantities of EGFR. The data presented below show that the sensitivity of the ELISA is approximately 10x greater than that of Western blotting. The bands shown in the Western blot data were developed using rabbit anti-EGFR, and an alkaline phosphatase conjugated anti-rabbit IgG followed by chemiluminescent substrate and autoradiography.

Detection of full length EGFR by ELISA vs Western Blot:



Precision

1. Intra-Assay Precision

Samples of known human full length EGFR concentration were assayed in replicates of 12 to determine precision within an assay.

	Sample 1	Sample 2	Sample 3
Mean (ng/ml)	9.58	4.88	2.19
SD	0.56	0.43	0.15
%CV	5.83	8.79	6.68
SD = Standard Deviation CV = Coefficient of Variation			

2. Inter-Assay Precision

Samples were assayed 36 times in multiple assays to determine precision between assays.


	Sample 1	Sample 2	Sample 3
Mean (ng/ml)	9.61	4.88	2.16
SD	0.79	0.52	0.16
%CV	6.66	10.71	7.21
SD = Standard Deviation CV = Coefficient of Variation			

Recovery

The recovery of full length EGFR added to an EGFR-negative cell lysate (3T3-L1 cells), adjusted to 200 µg/ml, averaged 106% when diluted in *Standard Diluent Buffer*.


Specificity

This EGFR ELISA kit is specific for measurement of human full length EGFR protein. The kit does not detect truncated forms of EGFR, which lack the cytoplasmic domain. As shown in the figure below, this kit detects cellular levels of EGFR but not soluble EGFR in the supernatant of A431 cell culture.



This kit recognizes full length EGFR regardless of phosphorylation state. The assay is designed to allow normalization of EGFR content among samples to permit interpretation of results from other Phosphorylation Site Specific EGFR kits available from Invitrogen. The figure below shows the results obtained when purified EGFR was autophosphorylated *in vitro*. The data indicate that this ELISA detects both phosphorylated and non-phosphorylated forms of EGFR, whereas the Phosphorylation Site Specific EGFR ELISAs only react with phosphorylated protein.

Full length EGFR ELISA detects both phosphorylated and non-phosphorylated EGFR



ELISAs to detect 10 ng/ml of EGFR proteins


Linearity of Dilution

A431 cells were grown in tissue culture medium containing 10% fetal bovine serum and lysed with Cell Extraction Buffer. This lysate was adjusted to 10 ng/ml full length EGFR and serially diluted in *Standard Diluent Buffer* over the range of the assay. Linear regression analysis of samples versus the expected concentration yielded a correlation coefficient of 0.99 in both cases.

Dilution	Cell Lysate		
	Measured (ng/ml)	Expected (ng/ml)	% Expected
1/2	9.74	9.74	100
1/4	4.92	4.87	101
1/8	2.79	2.43	106
1/16	1.32	1.22	109
1/32	0.65	0.61	107

Parallelism

Natural EGFR from A431 cell lysate was serially diluted in *Standard Diluent Buffer*. The optical density of each dilution was plotted against the EGFR standard curve. Parallelism was demonstrated by the figure below and indicated that the Standard accurately reflects full length EGFR content in samples.



Limitations of the Procedure

Do not extrapolate the standard curve beyond the top standard point; the dose-response is non-linear in this region and accuracy is difficult to obtain. Dilute samples above the highest standard point with *Standard Diluent Buffer*; reanalyze these and multiply results by the appropriate dilution factor.

The influence of various extraction buffers has not been thoroughly investigated. The rate of degradation of native EGFR in various matrices has not been investigated. Although EGFR degradation in the Cell Extraction Buffer described in this protocol has not been seen to date, the possibility of this occurrence cannot be excluded.

Appendix

Troubleshooting Guide

Standard curve wells develop, but sample wells produce weak or no signal.

Cause: Improper sample preparation.

Solution 1: Make sure to prepare cell extracts in the protease inhibitor-supplemented Cell Extraction Buffer recommended in the protocol booklet. Other buffer formulations have not been evaluated.

Cause: Samples contain materials that interfere with the assay.

Solution 1: The Cell Extraction Buffer recommended in the protocol booklet contains SDS. This detergent can potentially interfere with the immunoassay. For this reason, we recommend that all samples be diluted by a factor of at least 1:10 using the Standard Diluent Buffer provided in the kit. This buffer also contains blocking proteins that will reduce background signal.

Cause: The concentration of the target analyte is too dilute.

Solution 1: When preparing the cell extracts, increase the number of cells per volume of protease inhibitor supplemented Cell Extraction Buffer. Ideally, the concentration of protein in each cell extract, as determined by the Quant-iT™ protein assay kit, will be between 1 and 10 mg/ml (Method 1) or 1 and 5 mg/ml (Method 2). It is recommended that 5-10 µg of total cellular protein as a starting point be loaded into each well.

Solution 2: Optimize the stimulation procedure and time.

Cause: A sample treatment step was not performed.

Solution 1: Certain analytes (e.g., ERK1/2 [pTpY185/187] and ERK1/2 Total) require a sample treatment step to improve performance with Invitrogen phosphoELISA™ kits. Please see the analyte-specific protocol booklet for information on sample treatment procedures.

Cause: Samples deteriorated during storage.

Solution 1: Make sure that the Cell Extraction Buffer is supplemented with phosphatase inhibitors and protease inhibitors just prior to use.

Solution 2: All samples should be stored frozen at –80°C.

Solution 3: Samples should be subjected to only one freeze-thaw cycle.

Solution 4: Some proteins can be lost by adsorption when stored in containers made of polystyrene or certain kinds of glass. Polypropylene tubes are best for storing samples.

Sample wells develop, but standard wells produce weak or no signal.

Cause: Improper dilution of standards.

Solution 1: Check reconstitution volume of standard.

Solution 2: Standard curves are generated by serially diluting the reconstituted standard. Check the serial dilution method.

Solution 3: Standards should be used within an hour of reconstitution and serial dilution.

Cause: Improper storage of standards.

Solution 1: Standards are provided as lyophilized powders that should be stored at 2–8°C. Once reconstituted, standard should be stored at –80°C.

Neither the standard curve wells nor the sample wells develop.

Cause: Insufficient horseradish peroxidase (HRP)-conjugated secondary antibody activity.

Solution 1: Check the dilution of the HRP secondary antibody.

Solution 2: The HRP secondary antibody must be freshly diluted for each assay.

Solution 3: The HRP secondary antibody must be stored at 2–8°C.

Solution 4: Sodium azide is an irreversible inhibitor of horseradish peroxidase enzyme activity. Make sure to dilute the HRP secondary antibody in the correct buffer. A quick test can be performed to determine if the HRP secondary antibody is active. Into a clean test tube, dispense 200 µl of the TMB substrate solution provided in the kit. This TMB substrate solution should be clear to slightly blue-green tinted. Next, pipette 2 µl of the HRP secondary antibody. The color of the TMB will change to an intense aqua blue instantaneously if the HRP has retained its enzyme activity.

Cause: Insufficient Detector Antibody.

Solution 1: The Detector Antibody must be stored at 2–8°C.

Solution 2: Improper dilution of Detector Antibody.

Cause: TMB solution lost activity.

Solution 1: The TMB solution should be clear before it is dispensed into the wells of the microtiter plate.

An intense aqua blue color indicates that the product is contaminated. Please contact Technical Support if this problem is noted. To avoid contamination, we recommend that the quantity required for an assay be dispensed into a disposable trough for pipetting. Any TMB solution left in the trough should be discarded.

Solution 2: Avoid contact of the TMB solution with items containing metal ions.

Standard curves are not developing consistently in between different runs.

Cause: Improper dilution of Anti-Rabbit IgG HRP Working Solution.

Solution 1: The Anti-Rabbit IgG HRP (100X) is in 50% glycerol. This solution is viscous. To ensure accurate dilution, allow Anti-Rabbit IgG HRP (100X) to reach room temperature. Gently mix. Pipette concentrate slowly. Remove excess concentrate solution from pipette tip by gently wiping with clean absorbent paper.

Solution 2: Check plate washing technique. Results can be effected if some liquid remains after aspiration.

Technical Support

Contact Us



For more troubleshooting tips, information, or assistance, please call, email, or go online to www.invitrogen.com/ELISA.

US:

Invitrogen Corporation
542 Flynn Road
Camarillo, CA 93012

Tel: 800-955-6288

E-mail: techsupport@invitrogen.com

Europe:

Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK

Tel: +44 (0) 141 814 6100

Fax: +44 (0) 141 814 6117

E-mail: eurotech@invitrogen.com

References

1. Prenzel, N., et al. (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocr. Relat. Cancer* 8:11-31.
2. Raymond, E., et al. (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. *Drugs* 60:15-23.
3. Mayes, E.L. and M.D. Waterfield (1984) Biosynthesis of the epidermal growth factor receptor in A431 cells. *EMBO J* 3:531-537.
4. Tang, C.K., et al. (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. *Cancer Res.* 60:3081–3087.
5. Biscardi, J.S., et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. *J. Biol. Chem.* 274(12):8335-8343.
6. Schooler, K., and H.S. Wiley (2000) Ratiometric assay of epidermal growth factor receptor tyrosine kinase activation. *Anal. Biochem.* 277:135-142.
7. Sibilio, M., et al. (2000) The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. *Cell* 102:211-220.
8. Keilhack, H., et al. (1998) Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. *J. Biol. Chem.* 273:24839-46.
9. Rodrigues, G.A., et al. (2000) A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. *Mol. Cell. Biol.* 20:1448-1459.














Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, please contact our Technical Support Representatives. Invitrogen warrants that all of its products will perform according to the specifications stated on the Certificate of Analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order. Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Support Representatives. **Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.**

Licensing Information

These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Explanation of symbols

Symbol	Description	Symbol	Description
	Catalogue Number		Batch code
	Research Use Only		<i>In vitro</i> diagnostic medical device
	Use by		Temperature limitation
	Manufacturer		European Community authorised representative
	Without, does not contain		With, contains
	Protect from light		Consult accompanying documents
	Directs the user to consult instructions for use (IFU), accompanying the product.		

Copyright © Invitrogen Corporation. 04 February 2010

NOTES

Human EGFR Assay Summary

Incubate 100 μ L Standard/Cell Extract (>1:10)
for 2 hours at RT



aspirate and wash 4x

Incubate 100 μ L of Detection Antibody
for 1 hour at RT



aspirate and wash 4x

Incubate 100 μ L of HRP Anti-Rabbit Antibody
for 30 minutes at RT




aspirate and wash 4x

Incubate 100 μ L of Stabilized Chromogen
for 30 minutes at RT



Add 100 μ L of Stop Solution and read at 450 nm
Total time: 4 hours



EGFR



HRP Anti-Rabbit
Antibody



Detection Antibody